ABSCI CORP (ABSI) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 86.49M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 18.28M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -126.20M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $86.49M | (m) | $18.28M | $-126.20M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $84.33M | (m) | $17.79M | $-123.43M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $81.42M | (m) | $18.32M | $-120.32M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $74.45M | (m) | $19.13M | $-119.05M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $73.18M | (m) | $20.24M | $-117.79M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $67.99M | (m) | $20.77M | $-113.12M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $63.86M | $4.53M | $19.45M | $-108.89M | (m) | 1408.45% | 429.03% | (m) | (m) |
| 2024-09-30 | $57.75M | $4.21M | $17.56M | $-103.85M | (m) | 1372.74% | 417.47% | (m) | (m) |
| 2024-06-30 | $50.80M | $3.25M | $14.60M | $-98.26M | (m) | 1562.92% | 449.29% | (m) | (m) |
| 2024-03-31 | $47.65M | $5.35M | $12.35M | $-114.53M | $865.00K | 891.08% | 231.05% | -132.40× | Reported |
| 2023-12-31 | $48.07M | $5.72M | $11.42M | $-115.52M | $1.01M | 840.63% | 199.65% | -114.37× | Reported |
| 2023-09-30 | $47.11M | $6.94M | $9.26M | $-111.87M | $1.09M | 679.16% | 133.50% | -102.35× | Reported |
| 2023-06-30 | $51.61M | $8.56M | $10.28M | $-116.53M | $1.14M | 602.77% | 120.11% | -101.95× | Reported |
| 2023-03-31 | $55.74M | $6.20M | $11.45M | $-102.43M | $1.10M | 899.44% | 184.80% | -93.29× | Reported |
| 2022-12-31 | $58.91M | $5.75M | $12.54M | $-106.75M | $972.00K | 1025.02% | 218.20% | -109.83× | Reported |
| 2022-09-30 | $63.36M | $5.64M | $14.75M | $-111.91M | $885.00K | 1122.99% | 261.40% | -126.46× | Reported |
| 2022-06-30 | $58.56M | $4.81M | $14.96M | $-105.09M | $1.37M | 1217.04% | 310.97% | -76.48× | Reported |
| 2022-03-31 | $53.36M | $4.54M | $12.20M | $-92.89M | $3.17M | 1175.91% | 268.75% | -29.29× | Reported |
| 2021-12-31 | $44.59M | $4.78M | $10.61M | $-75.24M | $3.43M | 932.37% | 221.83% | -21.92× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $11.45M | $4.78M | $420.00K | $-13.30M | $634.00K | 239.50% | 8.79% | -20.98× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |